Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHighmark Blueshield NENY specialty prior auth | Op…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentHighmark Blueshield NenyPolicy N/A

    Prior authorization and utilization management for specialty and injectable drugs and selected services

    Customize your policy alerts

    Sign up for all Highmark Blueshield Neny policy alerts

    Know when Highmark Blueshield Neny releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines authorization pathways and UM program assignments for specialty/injectable drugs and selected services for Highmark BlueShield members in specified states; informs providers how to determine plan-specific authorization requirements.

    Policy Summary
    PayerHighmark Blueshield Neny
    PolicyPrior authorization and utilization management for specialty and injectable drugs and selected services
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJun 1, 2026
    Next Review DateN/A
    Key ActionVerify member-specific authorization by calling the number on the back of the member's card, checking eligibility via Availity, or searching BlueExchange; include the specific J-/Q-/HCPCS code and diagnosis so requests route to Evolent or Highmark as designated.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    220+distinct codes listed
    Evolent/Highmarkprogram split
    3auth check options
    Multiple
    Gold Card entries

    Coverage Criteria and Management Assignment

    Management assignment (Evolent vs Highmark)

    Coverage/management assignment is presented as mappings; coverage decisions depend on matching the drug name, J-code, and diagnosis to the listed manager.

    UM assignment rule: When a listed J-code and associated oncology drug are submitted, the service is managed by the entity (Evolent or Highmark) indicated for that entry; Evolent manages most cancer diagnoses and Highmark manages other specified diagnoses.

    Providers must use the specific mapping lines to determine the correct UM manager and prior authorization pathway.

    Program management assignment (Evolent vs Highmark)

    Coverage/management assignment by diagnosis and J-code

    Program assignment: Services for most cancer diagnoses are managed by the Evolent Oncology UM Program; services for all other diagnoses are managed by Highmark.

    Mapping of specific drugs/J-codes to Evolent or Highmark is provided alongside each listed agent in this section.

    Management assignment criteria

    Coverage and management assignment by drug/code and diagnosis/site-of-care

    Management assignment: Drugs and biologics listed are mapped to management responsibility: Evolent for many oncology diagnoses under the Evolent Oncology UM Program; Highmark manages other diagnoses or specialty drugs as indicated. Site‑of‑care entries (where present) further associate specific J‑codes with site designations and the same program assignment.

    Providers must include the exact J‑/Q‑code, drug name, diagnosis and site‑of‑care on UM/prior authorization requests to route to the correct manager.

    UM routing by diagnosis and code

    Routing and management criteria by diagnosis and service

    UM routing: IF the service code is listed in this section AND the diagnosis is a cancer diagnosis managed by the Evolent Oncology UM Program, THEN the service is managed by Evolent; OTHERWISE services for non‑oncology diagnoses are managed by Highmark.

    Applies to codes and services listed throughout chunks 234–253; QMR and many device/supply codes are routed to Highmark Management Services or Highmark Advanced Imaging as indicated.

    Services listed under the Evolent Oncology UM Program are managed by Evolent for most cancer diagnoses; services for all other (non-cancer) diagnoses are managed by Highmark. Providers should use the program mapping on the J‑code / CPT / HCPCS line items to determine which UM program (Evolent vs Highmark) will handle prior authorization and utilization management for a given service.

    This excerpt contains no additional clinical exclusion statements. It reiterates the administrative program assignment: when a diagnosis maps to the Evolent Oncology UM Program the service is managed by Evolent; when the diagnosis is not an Evolent‑managed cancer diagnosis, Highmark manages the service.

    For oncology diagnoses the document assigns management to the Evolent Oncology UM Program. When the submitted diagnosis is a cancer diagnosis falling within the Evolent program mapping, prior authorization and UM for the associated oncology services and injectables will be routed to Evolent per the code‑to‑program mapping.

    For non‑cancer diagnoses the utilization management responsibility rests with Highmark. Services that do not meet the Evolent oncology diagnosis mapping should be routed to Highmark for prior authorization and UM processing.

    This partial segment does not list any explicit clinical exclusions (for example, specific procedures labeled 'not medically necessary'). The content is administrative in nature and focuses on mapping J‑codes and other codes to the managing entity rather than setting clinical exclusion rules.

    Management assignment is driven by the combination of the submitted code (J‑code, Q‑code, CPT/HCPCS) and the patient diagnosis: if the diagnosis corresponds to an Evolent‑managed oncology entry, the request is managed by Evolent; otherwise Highmark manages the request. The excerpt contains no stand‑alone clinical exclusion criteria; use the code‑to‑program mappings to determine routing.

    This portion is primarily an administrative mapping of procedure, device and supply codes to the managing entity. It indicates which codes are routed to Highmark Management Services and which diagnoses (primarily cancer diagnoses) are routed to Evolent, without adding independent clinical rules in the excerpt.

    Within the PET imaging code list the entry G0219 is noted as ‘PET IMAGING WHOLE BODY; MELANOMA FOR NON‑COVERED INDICATIONS’. This indicates a specific non‑covered use case is identified for that PET melanoma entry in the code mapping provided.

    Evolent manages services only for the diagnoses that are explicitly listed as Evolent‑managed in the mapping; all other diagnoses (i.e., diagnoses not mapped to Evolent) are managed by Highmark. Providers must submit the correct procedure/J‑code and diagnosis so the request is routed to the appropriate manager.

    The document reiterates the program split: services for most cancer diagnoses are managed by the Evolent Oncology UM Program, and services for non‑oncology diagnoses are managed by Highmark. The excerpt does not provide further clinical limitations or 'not medically necessary' statements.

    No explicit 'not medically necessary' determinations are stated in this small excerpt. The content focuses on administrative mapping and program assignment rather than defining clinical coverage denials.

    This partial section contains no explicit 'not medically necessary' language. It enumerates J‑codes and associated agents and indicates program assignment (Evolent, Highmark or both) rather than defining clinical exclusions.

    No 'not medically necessary' statements appear in this excerpt. The listed entries describe mapping of other specialty drug J‑codes to Highmark Specialty or Evolent as appropriate, without introducing clinical exclusion criteria in this fragment.

    CPT / HCPCS / J-code & Device Code Lists

    Behavioral Health / TMS / BH Residential HCPCS/CPTmixed
    H0032MENTAL HEALTH SERVICE PLAN DEVELOPMENT BY NON-PHYSICIAN
    H2019THERAPEUTIC BEHAVIORAL SERVICES, PER 15 MINUTES
    H0015ALCOHOL AND/OR DRUG SERVICES; INTENSIVE OUTPATIENT TREATMENT
    S9480INTENSIVE OUTPATIENT PSYCHIATRIC SERVICES, PER DIEM
    H0035INTENSIVE OUTPATIENT PSYCHIATRIC SERVICES, PER DIEM
    S0201PARTIAL HOSPITALIZATION SERVICES, LESS THAN 24 HOURS, PER DIEM
    90868TRANSCRANIAL MAGNETIC STIMULATION (TMS) THERAPEUTIC REPETITIVE TMS
    90869TMS MOTOR THRESHOLD RE-DETERMINATION WITH DELIVERY AND MANAGEMENT
    H0019BEHAVIORAL HEALTH; LONG-TERM RESIDENTIAL, PER DIEM
    T2048BEHAVIORAL HEALTH; LONG-TERM CARE RESIDENTIAL, PER DIEM
    ABA / Adaptive Behavior CPT GroupCPT
    0362TTMS-RELATED / SITE SPECIFIC (temporary placeholder)
    0373TTMS-RELATED / SITE SPECIFIC (temporary placeholder)
    97151ASSESSMENT/PLAN DEVELOPMENT BY CERTIFIED BEHAVIOR ANALYST, FIRST 15 MIN
    97152BEHAVIOR IDENTIFICATION ASSESSMENT, EACH 15 MIN
    97153BEHAVIORAL TREATMENT, PARENT TRAINING, FAMILY-RELATED
    97154ADAPTIVE BEHAVIOR TREATMENT BY TECHNICIAN
    97155ADAPTIVE BEHAVIOR TREATMENT SUPERVISION BY BCBA
    97156FAMILY ADAPTIVE BEHAVIOR TREATMENT, EACH 15 MIN
    97157FAMILY ADAPTIVE BEHAVIOR TREATMENT, MODIFICATION
    97158GROUP ADAPTIVE BEHAVIOR TREATMENT
    Ambulance CodesHCPCS
    A0426AMBULANCE SERVICE, ADVANCED LIFE SUPPORT, NON-EMERGENCY TRANSPORT, LEVEL 1 (ALS1)
    A0430AMBULANCE SERVICE, CONVENTIONAL FIXED WING, ONE WAY
    A0431AMBULANCE SERVICE, CONVENTIONAL ROTARY WING, ONE WAY
    Bariatric Surgery CPTsCPT
    43644LAPAROSCOPY, GASTRIC BYPASS WITH ROUX-EN-Y (<=150 cm)
    43645LAPAROSCOPY, GASTRIC BYPASS WITH SMALL INTESTINE RECONSTRUCTION
    43647LAPAROSCOPY, IMPLANTATION/REPLACEMENT OF GASTRIC NEUROSTIMULATOR ELECTRODES, ANTRUM
    43771LAPAROSCOPIC REVISION OF ADJUSTABLE GASTRIC RESTRICTIVE DEVICE COMPONENT
    43773LAPAROSCOPY, REMOVAL/REPLACEMENT OF ADJUSTABLE GASTRIC RESTRICTIVE DEVICE COMPONENT
    43774LAPAROSCOPY, REMOVAL OF ADJUSTABLE GASTRIC RESTRICTIVE DEVICE & PORT
    43775LAPAROSCOPY, SLEEVE GASTRECTOMY
    43843GASTRIC RESTRICTIVE PROCEDURE, OTHER THAN VERTICAL-BANDED GASTROPLASTY
    43845BILIOPANCREATIC DIVERSION WITH DUODENAL SWITCH
    43847GASTRIC RESTRICTIVE PROCEDURE WITH GASTRIC BYPASS; SHORT LIMB ROUX-EN-Y
    1–10 of 11
    1/2
    Bone Growth / Capsule Endoscopy / DMEmixed
    E0747OSTEOGENESIS STIMULATOR, ELECTRICAL, NON-INVASIVE (OTHER THAN SPINAL)
    E0760OSTEOGENESIS STIMULATOR, LOW INTENSITY ULTRASOUND, NON-INVASIVE
    91110GASTROINTESTINAL TRACT IMAGING, INTRALUMINAL (CAPSULE ENDOSCOPY), INTERPRETATION & REPORT (ESOPHAGUS THROUGH ILEUM)
    91111CAPSULE ENDOSCOPY, WITH INTERPRETATION AND REPORT (ESOPHAGUS)
    Cardiac Devices - Pacemakers/ICDs and Related HCPCS/Codesmixed
    33206Insertion of new or replacement permanent pacemaker with transvenous electrode(s); atrial
    33207...; ventricular
    33208...; atrial and ventricular
    33214Upgrade of implanted pacemaker system to dual chamber (includes generator removal, testing, insertion)
    33216Insertion of a single transvenous electrode, pacemaker or implantable defibrillator
    33217Insertion of 2 transvenous electrodes, pacemaker or implantable defibrillator
    33224Insertion of pacing electrode, cardiac venous system, for LV pacing, with attachment to existing generator
    33227Removal of pacemaker pulse generator with replacement; single lead
    33228Removal/replacement; dual lead
    33229Removal/replacement; multiple lead system
    1–10 of 33
    1/4
    Cardiac Imaging & Advanced/Cardiac CT/MRI CodesCPT
    75571CT, heart, without contrast, with quantitative coronary calcium
    75572CT, heart, with contrast for evaluation of cardiac structure and morphology
    75573CT, heart with contrast for congenital heart disease (includes 3D postprocessing)
    75574CT angiography, heart, coronary arteries and bypass grafts, with contrast and 3D postprocessing
    0331TMyocardial sympathetic innervation imaging, planar and tomographic SPECT mapping (cross-mapped)
    0332TTomographic SPECT assessment variant
    33340Percutaneous transcatheter closure of the left atrial appendage with endocardial implant
    33361TAVR percutaneous femoral artery approach
    33362TAVR open femoral artery approach
    33363TAVR open axillary artery approach
    1–10 of 18
    1/2
    Cardiac Surgery & Cath / EP / Structural CodesCPT
    34709Placement of extension prosthesis distal to common iliac or proximal to renal artery for EVAR
    34710Delayed placement of extension prosthesis for EVAR
    34711Each additional vessel treated (listed separately)
    34712Transcatheter delivery of enhanced fixation device to endograft
    92920PTCA; single major coronary artery or branch
    92928Placement of intracoronary stent(s) with PTCA; single major coronary artery
    92937PTCA of or through coronary artery bypass graft
    92943Coronary thrombectomy (when performed)
    93580Invasive hemodynamic monitoring procedures (example cross-mapped)
    0408TInsertion/replacement of permanent cardiac contractility modulation system, pulse generator only
    1–10 of 12
    1/2
    Cataract / CMRI / Cochlear / Cornea / PET Myocardial CodesCPT
    66989Complex extracapsular cataract removal with IOL, complex techniques or devices
    66991Cataract removal with insertion of IOL and anterior segment aqueous drainage device
    75557Cardiac MRI without contrast, morphology and function
    75559CMRI with stress imaging
    75561CMRI with contrast sequences
    75563CMRI with contrast and stress
    75565CMRI velocity flow mapping
    69714Implantation, osseointegrated implant, temporal bone (listening device)
    69930Cochlear implant insertion
    L8614Cochlear device internal and external components
    1–10 of 15
    1/2
    Craniotomy / Neurostimulator / CT Head/Neck/Thorax SeriesCPT
    61863Stereotactic implantation of neurostimulator electrode array, twist drill/burr hole (first array)
    61867... with intraoperative microelectrode recording
    70450CT head without contrast
    70460CT head with contrast
    70470CT head without & with contrast
    70480CT orbit without contrast
    70481CT orbit with contrast
    70482CT orbit without & with contrast
    70486CT maxillofacial without contrast
    70487CT maxillofacial with contrast
    1–10 of 16
    1/2
    CT Spine / Abdomen / Colonography SeriesCPT
    71250CT thorax without contrast
    71260CT thorax with contrast
    71270CT thorax without & with contrast
    72125CT cervical spine without contrast
    72126CT cervical spine with contrast
    72127CT cervical spine without & with contrast
    72128CT thoracic spine without contrast
    72129CT thoracic spine with contrast
    72130CT thoracic spine without & with contrast
    72131CT lumbar spine without contrast
    1–10 of 22
    1/3
    Echo / Cardiac Unlisted / QMR Mappingsmixed
    76380CT limited or localized follow-up study
    0711TCTA noninvasive arterial plaque analysis (data prep/transmission)
    0712TCTA noninvasive arterial plaque analysis (quantification)
    0713TCTA plaque analysis interpretation & report
    933193D echocardiographic imaging and postprocessing during TEE or TTE for congenital anomalies
    93350Echocardiography, transthoracic, real-time with image documentation (2D)
    93351Echocardiography TTE with MMODE during stress
    0648TQuantitative magnetic resonance for single organ (QMR)
    0649TQMR obtained with diagnostic MRI of same anatomy
    0697TQMR multiple organs without diagnostic MRI

    What Providers Must Do

    Note

    How to verify authorization

    Providers must verify member-specific authorization requirements before submitting any prior authorization (PA) or utilization management (UM) request. Check the phone number on the back of the member’s ID card, confirm eligibility and benefits via Availity, or search BlueExchange® through the provider portal to determine whether PA is required for the member’s plan.

    • How to verify authorization: call the number on the back of the member's card; check Availity eligibility/benefits; search BlueExchange through local provider portal.
    Prior Authorization

    Prior authorization / utilization management routing

    Prior authorization and UM routing are code- and diagnosis-dependent. Many procedures and drugs in the code lists are designated either Highmark Management Services, Highmark Advanced Imaging, Highmark Specialty/Site-of-Care, or Evolent (Evolent Oncology UM Program). Submit the exact CPT/HCPCS/J-/Q-code and the member’s diagnosis on the request so the service is routed to the correct manager.

    • Many listed procedures are designated as Highmark Management Services, Highmark Advanced Imaging, Highmark Specialty (including Site of Care), or Evolent Oncology — use the code-to-program mapping when requesting UM review.

    Site-of-Care Designations

    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Step Therapy and Sequencing Notes

    Initial therapy criteriaNotes
    No top-level initial therapy criteria specified in this partial section.The document lists program-level management assignments for listed J-codes and drugs but does not define initial therapy requirements or clinical start criteria in the excerpt provided.
    0 top-level nodesSee UM program mappings for management routing; clinical initial-therapy rules are not present in this fragment.
    Step therapy sequencing present?Summary
    No explicit step therapy sequence described in this partial section.The excerpt states that no explicit step therapy requirements are specified here; prior authorization and UM routing are determined by J-code and diagnosis mapping.
    Agent-specific authorization required when codes map multiple agentsExplanation / Example
    Yes — agent-specific prior authorization criteria apply when multiple agents share a site-code grouping.Entries show J9173 grouped to multiple agents (e.g., durvalumab mapped to nivolumab, pembrolizumab, combinations) and are labeled Evolent*/Highmark — providers must apply agent-specific prior authorization even when codes share a site-of-care grouping.
    Step therapy rules provided in excerptNotes
    No — no step therapy rules are provided in this excerpt.The document indicates prior authorization and UM program assignment by J-/Q-code and diagnosis, but explicit step therapy algorithms or required prior agents are not defined in the provided sections.

    Biosimilar & Originator Product Notes

    Note
    Note

    Background

    Background: this document segment lists specialty and injectable drugs, procedure and supply codes, and maps each code or drug entry to a utilization management program. The mapping establishes that the Evolent Oncology UM Program manages utilization for most cancer diagnoses while Highmark manages services for other diagnoses and many non‑oncology specialty drugs and device codes.

    Definitions and Designations

    NOC** and program assignment summary
    NOC** label usageNOC** is used throughout the drug and device lists to designate 'Not Otherwise Classified' specialty drug entries assigned to UM programs (appears as code label for multiple entries).
    Evolent vs Highmark splitThe document consistently maps specific J-/Q-/HCPCS codes to either the Evolent Oncology UM Program (manages most cancer diagnoses) or to Highmark-managed programs for non-cancer diagnoses or specific specialty drugs.
    Highmark Management designationsInternal management labels (Highmark Medical Injectable, Highmark Specialty, Highmark Management Services, Highmark Advanced Imaging, Gold Card Eligible) are applied to listed CPT/HCPCS/J/Q entries to direct UM routing.
    Evolent Oncology UM Program
    Evolent Oncology UM ProgramProgram that manages utilization for most cancer diagnoses; entries marked Evolent indicate prior authorization/UM is managed by Evolent for those cancer diagnoses.

    Revision History

    Policy Summary
    PayerHighmark Blueshield Neny
    PolicyPrior authorization and utilization management for specialty and injectable drugs and selected services
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJun 1, 2026
    Next Review DateN/A
    Key ActionVerify member-specific authorization by calling the number on the back of the member's card, checking eligibility via Availity, or searching BlueExchange; include the specific J-/Q-/HCPCS code and diagnosis so requests route to Evolent or Highmark as designated.
    SourceLink
    On This Page
    Coverage Criteria and Management AssignmentCPT / HCPCS / J-code & Device Code ListsWhat Providers Must DoSite-of-Care DesignationsStep Therapy and Sequencing NotesBiosimilar & Originator Product NotesBackgroundDefinitions and DesignationsRevision History
  1. Procedure code and diagnosis routing: include the CPT/HCPCS/J-/Q-code and indicate whether the diagnosis is cancer-related to ensure routing to Evolent Oncology UM Program (Evolent) or Highmark as specified.
  2. Use code-to-program mapping for routing: follow the management designation shown next to each listed code when submitting PA/UM requests.
  3. Prior Authorization

    J-code-based UM assignment

    Certain injectable specialty and oncology drugs are assigned to a specific UM program. For drugs listed with J- or Q-codes, providers must include the drug name and the exact HCPCS/J-/Q-code on the prior authorization or UM submission. Management responsibility often depends on diagnosis (Evolent for most cancer diagnoses; Highmark for non-oncology or other specialty assignments).

    • J-code-based UM assignment: prior authorization/UM management is designated per listed J/Q codes and associated drug names; include the J-/Q-code and drug name on the request.
    • Include specific drug and J-code information: list the exact drug and corresponding J-/Q-code on PA/UM requests.
    • Include correct J-code and drug name to ensure accurate routing and adjudication.
    • Submit correct code and site-of-care when applicable (site-of-care designations are shown for some oncology/site-of-care drugs).
    • Use specific J-/Q-code for routing: management assignment (Evolent vs Highmark) is determined by the code and diagnosis.
    Prior Authorization

    MRI/MRA prior authorization routing

    Prior authorization is required for many MRI/MRA/QMR services designated as Highmark Advanced Imaging (some are Gold Card Eligible). When requesting prior authorization for MRI/MRA/QMR procedures, reference the exact CPT/HCPCS/QMR code and route the request to Highmark Advanced Imaging as indicated.

    • MRI/MRA prior authorization routing: many MRI and MRA CPT/HCPCS codes (for example 70549, 70551, 73718–73723, 74181–74183, 0610T–0612T, S8037, S8042) are designated Highmark Advanced Imaging.
    • QMR codes (0649T, 0697T, 0698T) and other quantitative MRI codes are routed to Highmark Advanced Imaging.
    • Gold Card Eligible: some advanced imaging codes are marked Gold Card Eligible — follow plan-specific Gold Card rules where applicable.
    Prior Authorization

    Prior authorization required for select therapy codes

    Certain therapy and rehabilitation codes require prior authorization when routed to Highmark Physical Medicine/Highmark Physical. Include the therapy CPT code(s) and relevant clinical rationale when submitting PA/UM requests.

    • Prior authorization required for select therapy codes effective 2/1/2020: OT codes 97129, 97130 and physical/therapy codes 97139, 97164 require prior authorization.
    • Physical Medicine routing: these therapy codes are managed by Highmark Physical Medicine / Highmark Physical.
    • When submitting UM requests for therapy codes, include the primary procedure code, therapy code(s), clinical rationale, and number of units/sessions.
    Prior Authorization

    Prior authorization routing and required codes

    Certain device, powered vehicle, and accessory codes are managed by Highmark Management Services and require the proper procedure or supply code on UM/PA submissions. Include model/brand details when applicable.

    • Each listed powered vehicle and accessory code (for example E1230, E1239, E2298, E2324, E2327, K0011, K0012, K0014, K0098, K0800–K0899, K0884–K0891, K0898–K0899) is managed by Highmark Management Services.
    • Required coding on UM requests: include the applicable HCPCS/CPT/L-code (e.g., K0884, K0885, L1840, L3971, L6647, 0648T, 0649T, 0697T, 0698T, etc.) and device model/brand when requested.
    • Coding documentation guidance: for QMR/QMR-related and reconstructive/cosmetic codes, include the primary procedure, clinical rationale, and any QMR code details on the request.
    Denial Risk

    Program assignment and routing impact

    Management assignment affects authorization routing and may impact timeliness of review. Services in the Evolent Oncology UM Program are managed by Evolent for most cancer diagnoses and by Highmark for other diagnoses; submitting to the wrong manager can delay or jeopardize authorization.

    • Program routing for oncology vs non-oncology diagnoses: for items listed under the Evolent Oncology UM Program, indicate whether the diagnosis is cancer-related — Evolent manages most cancer diagnoses; Highmark manages non-cancer diagnoses.
    • Management routing affects authorization: incorrect routing (e.g., sending an oncology cancer diagnosis case to Highmark instead of Evolent) may cause delayed review or denial risk.
    • When in doubt, include the diagnosis and the specific code on the request to ensure correct routing to Evolent or Highmark.
    Documentation Required

    What to include on UM/PA requests

    When submitting prior authorization or UM requests: include the exact CPT/HCPCS/J-/Q-code, the associated drug name (for injectables), the member’s diagnosis, the site of care (if applicable), and the clinical rationale. This ensures the request is routed to the correct program (Evolent Oncology UM Program, Highmark Management Services, Highmark Advanced Imaging, Highmark Specialty, or Highmark Site of Care) and reduces the risk of delays or denials.

    • Code-specific routing requirement: prior authorization or UM submissions must reference the exact procedure or HCPCS/J-/Q-code to route the service to the designated manager.
    • Include correct J-code and drug name and submit correct code and site-of-care when applicable.
    • Use code-to-program mapping and indicate the diagnosis (oncology vs non-oncology) to direct the request to Evolent or the appropriate Highmark program.
    Evolent-managed examplesMany oncology J-code groupings (e.g., J9028 groupings, J9150–J9196 series) are annotated Evolent or Evolent*/Highmark indicating Evolent management for cancer diagnoses.
    Routing implicationProviders must submit the specific J-code and diagnosis to determine whether Evolent or Highmark manages the prior authorization request.
    Gold Card Eligible (administrative label)
    Gold Card EligibleAdministrative designation applied to selected imaging and procedural services in the mapping (appears alongside many MRI/MRA and advanced imaging entries).
    Not operationally defined hereThe excerpt uses the label 'Gold Card Eligible' but does not provide an operational definition within this fragment.
    Used with Highmark Advanced ImagingGold Card Eligible often appears together with Highmark Advanced Imaging designations in imaging code mappings.
    Evolent Oncology UM Program (repeated)
    Evolent Oncology UM Program (reaffirmed)External utilization management program that manages services for most cancer diagnoses; multiple list entries reiterate Evolent as the oncology UM manager.
    Provider actionWhen submitting UM requests for oncology agents, include the specific J-code and diagnosis to route to Evolent if the diagnosis is cancer-related.
    Mixed management entriesSome entries are marked Evolent*/Highmark indicating shared or conditional management depending on diagnosis or agent.
    Internal management designations
    Internal management designationsHighmark Advanced Imaging, Highmark Management Services, Gold Card Eligible, Highmark Specialty and similar labels are applied to CPT/HCPCS/J-code entries to direct UM routing internally.
    Applied across servicesThese designations appear across imaging, procedural, device, and specialty drug lists to indicate the appropriate internal manager for authorization.
    Providers must reference code mappingProviders should use the code-to-program mapping in the list to determine the correct management assignment and where to submit prior authorization requests.
    Evolent Oncology UM Program (additional reference)
    Evolent Oncology UM Program (repeat)Evolent manages utilization for most cancer diagnoses; repeated label entries emphasize this assignment across oncology code lists.
    Mapping importanceThe document pairs J-codes with management labels—review each mapping line to determine whether a specific oncology drug is Evolent-managed.
    Gold Card Eligible (repeat)
    Gold Card Eligible (administrative)Label appears repeatedly across imaging and procedural code mappings indicating administrative treatment for selected services; used as a routing flag in the list.
    No operational definition in excerptThe snippet uses the term but does not define Gold Card processes or thresholds in this excerpt.
    Evolent Oncology UM Program (repeated label)
    Evolent Oncology UM Program (repeated label)Appears multiple times to designate oncology management responsibility for cancer diagnoses across the code lists.
    Check mapping per codeProviders must consult each listed code's management label (Evolent vs Highmark) to route prior authorization correctly.
    Evolent vs Highmark management assignment
    Evolent vs Highmark assignment (summary)Evolent manages most cancer diagnoses via the Evolent Oncology UM Program; Highmark manages non-cancer diagnoses and certain specialty drugs—mappings in the list indicate the assigned manager per code.
    Examples of splitEntries marked Evolent*/Highmark show conditional or shared management depending on diagnosis/agent (see J9173, J9028 groups).
    Evolent Oncology UM Program (reiteration)
    Evolent Oncology UM Program (reiteration)Reiterated as the managing entity for many oncology-related authorization entries across the document.
    Reference guidanceFor oncology J-codes, providers should reference the mapping lines to determine if Evolent manages the request based on diagnosis.
    Evolent Oncology UM Program (authorization role)
    Evolent Oncology UM Program (commercial note)Designated manager for many oncology J-code entries; repeated label underscores Evolent's role in authorizations for cancer diagnoses.
    Highmark roleHighmark still manages non-cancer diagnoses and certain specialty drugs as indicated in mappings adjacent to Evolent labels.
    Highmark Specialty (role)
    Highmark SpecialtyHighmark's specialty drug management unit (Highmark Specialty) is the listed manager for many non-Evolent-managed specialty drugs and certain gene therapies in the list.
    Example assignmentsGene therapies and some high-cost biologics (e.g., J1412–J1414, J3398–J3399) are assigned to Highmark Specialty in the mappings.
    Evolent Oncology UM Program (confirmation)
    Evolent Oncology UM Program (confirming) Consistently used across the oncology sections to indicate Evolent manages utilization for most cancer diagnoses.
    Provider actionSubmit the specific J-code and diagnosis to determine Evolent vs Highmark routing for the authorization request.
    QMR (Quantitative Magnetic Resonance) codes
    QMR codes listedQMR codes (0648T, 0649T, 0697T, 0698T) are identified as Quantitative Magnetic Resonance services for tissue composition analysis and are routed to Highmark Advanced Imaging per the mapping.
    QMR purposeQMR is defined as Quantitative Magnetic Resonance for analysis of tissue composition (fat, iron, water content) including multiparametric acquisition, data prep, interpretation and report.
    Gold Card/ManagementQMR codes are marked Highmark Advanced Imaging and Gold Card Eligible in the policy excerpt.
    QMR (short definition)
    QMR definition (short)QMR = Quantitative Magnetic Resonance (analysis of tissue composition) — codes include 0648T, 0649T, 0697T, 0698T as listed.
    Routing noteThese QMR codes are routed to Highmark Advanced Imaging per the code mapping lines.
    Initial therapy criteria (absence)
    Not specified in this partial sectionNo top-level initial therapy criteria are provided in this excerpt — initial therapy nodes are not specified in the partial section.
    Provider implicationFor drug-specific initial therapy requirements, refer to the full UM program or product-specific criteria outside this excerpt.